Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe.
Pursuing Later Treatment Options II (PLATO II) project team; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group; Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A, Jansen K, Masquelier B, García F, De Wit S, Stephan C, Obel N, Fätkenhaeuer G, Castagna A, Sambatakou H, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Pursuing Later Treatment Options II (PLATO II) project team, et al. Among authors: podzamczer d. J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):294-9. doi: 10.1097/QAI.0b013e31823fe66b. J Acquir Immune Defic Syndr. 2012. PMID: 22083070
Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
Gatell JM, González-Lahoz J, Clotet B, Antunes F, Kasparova L, Gil-Aguado A, Saballs P, Santamaria JM, Podzamczer D, Miro JM, Jou A, Verdejo J, Doroana M, Thomis J. Gatell JM, et al. Among authors: podzamczer d. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul;12(3):249-58. doi: 10.1097/00042560-199607000-00004. J Acquir Immune Defic Syndr Hum Retrovirol. 1996. PMID: 8673528 Clinical Trial.
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM. García F, et al. Among authors: podzamczer d. AIDS. 1999 Dec 3;13(17):2377-88. doi: 10.1097/00002030-199912030-00009. AIDS. 1999. PMID: 10597779 Clinical Trial.
Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
Arnaiz JA, Mallolas J, Podzamczer D, Gerstoft J, Lundgren JD, Cahn P, Fätkenheuer G, D'Arminio-Monforte A, Casiró A, Reiss P, Burger DM, Stek M, Gatell JM; BEST Study Team. Arnaiz JA, et al. Among authors: d arminio monforte a, podzamczer d. AIDS. 2003 Apr 11;17(6):831-40. doi: 10.1097/00002030-200304110-00008. AIDS. 2003. PMID: 12660530 Clinical Trial.
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project].
Jaén A, Casabona J, Esteve A, Miró JM, Tural C, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Masabeu A, García I, Dorca E, Altès J, Navarro G, Podzamczer D, Villalonga C, Clotet B, Gatell JM; Grupo de Estudio PISCIS. Jaén A, et al. Among authors: podzamczer d. Med Clin (Barc). 2005 Apr 16;124(14):525-31. doi: 10.1157/13073938. Med Clin (Barc). 2005. PMID: 15847748 Spanish.
Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort.
Berenguer J, Pérez-Elías MJ, Bellón JM, Knobel H, Rivas-González P, Gatell JM, Miguélez M, Hernández-Quero J, Flores J, Soriano V, Santos I, Podzamczer D, Sala M, Camba M, Resino S; Spanish Abacavir, Lamivudine, and Zidovudine Cohort Study Group. Berenguer J, et al. Among authors: podzamczer d. J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):154-9. doi: 10.1097/01.qai.0000194231.08207.8a. J Acquir Immune Defic Syndr. 2006. PMID: 16394846
Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
Miro JM, Lopez JC, Podzamczer D, Peña JM, Alberdi JC, Martínez E, Domingo P, Cosin J, Claramonte X, Arribas JR, Santín M, Ribera E; GESIDA 04/98 Study Group. Miro JM, et al. Among authors: podzamczer d. Clin Infect Dis. 2006 Jul 1;43(1):79-89. doi: 10.1086/504872. Epub 2006 May 31. Clin Infect Dis. 2006. PMID: 16758422 Clinical Trial.
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group. Jaén A, et al. Among authors: podzamczer d. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20. doi: 10.1097/qai.0b013e31815ee282. J Acquir Immune Defic Syndr. 2008. PMID: 18297762
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
Antiretroviral Therapy Cohort Collaboration (ART-CC); Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miró JM, Staszewski S, Sterne JA. Antiretroviral Therapy Cohort Collaboration (ART-CC), et al. AIDS. 2008 Nov 30;22(18):2481-92. doi: 10.1097/QAD.0b013e328318f130. AIDS. 2008. PMID: 19005271 Free PMC article.
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.
Antiretroviral Therapy Cohort Collaboration (ART-CC); Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Antiretroviral Therapy Cohort Collaboration (ART-CC), et al. Clin Infect Dis. 2009 Apr 15;48(8):1138-51. doi: 10.1086/597468. Clin Infect Dis. 2009. PMID: 19275498 Free PMC article.
363 results